267 related articles for article (PubMed ID: 32006900)
21. Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma.
Lu ZW; Wen D; Wei WJ; Han LT; Xiang J; Wang YL; Wang Y; Liao T; Ji QH
Oncol Rep; 2020 Mar; 43(3):783-794. PubMed ID: 31922231
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
Kozakai Y; Kamada R; Kiyota Y; Yoshimura F; Tanino K; Sakaguchi K
Bioorg Med Chem Lett; 2014 Dec; 24(24):5593-5596. PubMed ID: 25466181
[TBL] [Abstract][Full Text] [Related]
23. Targeting the PPM1D phenotype; 2,4-bisarylthiazoles cause highly selective apoptosis in PPM1D amplified cell-lines.
Cheeseman MD; Faisal A; Rayter S; Barbeau OR; Kalusa A; Westlake M; Burke R; Swan M; van Montfort R; Linardopoulos S; Jones K
Bioorg Med Chem Lett; 2014 Aug; 24(15):3469-74. PubMed ID: 24953599
[TBL] [Abstract][Full Text] [Related]
24. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
[TBL] [Abstract][Full Text] [Related]
25. Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1).
Hayashi R; Tanoue K; Durell SR; Chatterjee DK; Jenkins LM; Appella DH; Appella E
Biochemistry; 2011 May; 50(21):4537-49. PubMed ID: 21528848
[TBL] [Abstract][Full Text] [Related]
26. PP2Cdelta (Ppm1d, WIP1), an endogenous inhibitor of p38 MAPK, is regulated along with Trp53 and Cdkn2a following p38 MAPK inhibition during mouse preimplantation development.
Hickson JA; Fong B; Watson PH; Watson AJ
Mol Reprod Dev; 2007 Jul; 74(7):821-34. PubMed ID: 17219434
[TBL] [Abstract][Full Text] [Related]
27. Fortifying p53 - beyond Mdm2 inhibitors.
Sriraman A; Li Y; Dobbelstein M
Aging (Albany NY); 2016 Sep; 8(9):1836-1837. PubMed ID: 27688014
[No Abstract] [Full Text] [Related]
28. PPM1D activity promotes the replication stress caused by cyclin E1 overexpression.
Martinikova AS; Stoyanov M; Oravetzova A; Kok YP; Yu S; Dobrovolna J; Janscak P; van Vugt M; Macurek L
Mol Oncol; 2024 Jan; 18(1):6-20. PubMed ID: 37067201
[TBL] [Abstract][Full Text] [Related]
29. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
[TBL] [Abstract][Full Text] [Related]
30. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function.
Proia DA; Nannenga BW; Donehower LA; Weigel NL
J Biol Chem; 2006 Mar; 281(11):7089-101. PubMed ID: 16352595
[TBL] [Abstract][Full Text] [Related]
31. PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Fons NR; Sundaram RK; Breuer GA; Peng S; McLean RL; Kalathil AN; Schmidt MS; Carvalho DM; Mackay A; Jones C; Carcaboso ÁM; Nazarian J; Berens ME; Brenner C; Bindra RS
Nat Commun; 2019 Aug; 10(1):3790. PubMed ID: 31439867
[TBL] [Abstract][Full Text] [Related]
32. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
[TBL] [Abstract][Full Text] [Related]
33. Increased wild-type p53-induced phosphatase 1 (Wip1 or PPM1D) expression correlated with downregulation of checkpoint kinase 2 in human gastric carcinoma.
Fuku T; Semba S; Yutori H; Yokozaki H
Pathol Int; 2007 Sep; 57(9):566-71. PubMed ID: 17685927
[TBL] [Abstract][Full Text] [Related]
34. PPM1D regulates p21 expression via dephoshporylation at serine 123.
Cao R; Zhang J; Zhang M; Chen X
Cell Cycle; 2015; 14(4):641-7. PubMed ID: 25590690
[TBL] [Abstract][Full Text] [Related]
35. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
[TBL] [Abstract][Full Text] [Related]
36. Wip1 phosphatase in breast cancer.
Emelyanov A; Bulavin DV
Oncogene; 2015 Aug; 34(34):4429-38. PubMed ID: 25381821
[TBL] [Abstract][Full Text] [Related]
37. WIP1 Promotes Homologous Recombination and Modulates Sensitivity to PARP Inhibitors.
Burdova K; Storchova R; Palek M; Macurek L
Cells; 2019 Oct; 8(10):. PubMed ID: 31619012
[TBL] [Abstract][Full Text] [Related]
38. Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression?
Fukami S; Riemenschneider MJ; Kohno M; Steiger HJ
Brain Tumor Pathol; 2016 Jul; 33(3):191-9. PubMed ID: 26942600
[TBL] [Abstract][Full Text] [Related]
39. PPM1D in Solid and Hematologic Malignancies: Friend and Foe?
Zhang L; Hsu JI; Goodell MA
Mol Cancer Res; 2022 Sep; 20(9):1365-1378. PubMed ID: 35657598
[TBL] [Abstract][Full Text] [Related]
40. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways.
Lu X; Nguyen TA; Moon SH; Darlington Y; Sommer M; Donehower LA
Cancer Metastasis Rev; 2008 Jun; 27(2):123-35. PubMed ID: 18265945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
